+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Neurological Biomarkers Market by Type (Genomic, Imaging, Metabolomic), Application (Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis), End-user - Forecast 2024-2030- Product Image
Global Neurological Biomarkers Market by Type (Genomic, Imaging, Metabolomic), Application (Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis), End-user - Forecast 2024-2030- Product Image
Sale

Global Neurological Biomarkers Market by Type (Genomic, Imaging, Metabolomic), Application (Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis), End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5454976
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neurological Biomarkers Market size was estimated at USD 8.98 billion in 2023, USD 10.24 billion in 2024, and is expected to grow at a CAGR of 14.05% to reach USD 22.56 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neurological Biomarkers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neurological Biomarkers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neurological Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acumen Pharmaceuticals, Inc, Alseres Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., bioMérieux SA, Imagilys, inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc., IXICO PLC, Merck KGaA, Proteome Sciences PLC, QIAGEN GmbH, Quanterix Corporation, Quest Diagnostics Incorporated, Rules-Based Medicine by Q2 Solutions, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Neurological Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Genomic
    • Imaging
    • Metabolomic
    • Proteomic
  • Application
    • Alzheimer’s Disease
    • Autism Spectrum Disorders
    • Multiple Sclerosis
    • Parkinson’s Disease
  • End-user
    • Hospital Laboratories
    • Independent Clinical Diagnostic Centers
    • Research Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Neurological Biomarkers Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neurological Biomarkers Market?
  3. What are the technology trends and regulatory frameworks in the Neurological Biomarkers Market?
  4. What is the market share of the leading vendors in the Neurological Biomarkers Market?
  5. Which modes and strategic moves are suitable for entering the Neurological Biomarkers Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Neurological Biomarkers Market, by Type, 2022 vs 2030
4.3. Neurological Biomarkers Market, by Application, 2022 vs 2030
4.4. Neurological Biomarkers Market, by End-user, 2022 vs 2030
4.5. Neurological Biomarkers Market, by Region, 2022 vs 2030
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of neurological disorders
5.1.1.2. Demand for cost-effective and non-invasive diagnostic system
5.1.1.3. Increasing preferences on early diagnosis & preventive treatment
5.1.2. Restraints
5.1.2.1. Stringent government regulations for approvals
5.1.3. Opportunities
5.1.3.1. Growing R&D focus for advancements in biomarkers
5.1.3.2. Emerging single-cell biosensors
5.1.3.3. Growth of low-cost clinical trials in developing countries
5.1.4. Challenges
5.1.4.1. Ethical problems and acceptance issues of neurological disorders
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization
6. Neurological Biomarkers Market, by Type
6.1. Introduction
6.2. Genomic
6.3. Imaging
6.4. Metabolomic
6.5. Proteomic
7. Neurological Biomarkers Market, by Application
7.1. Introduction
7.2. Alzheimer’s Disease
7.3. Autism Spectrum Disorders
7.4. Multiple Sclerosis
7.5. Parkinson’s Disease
8. Neurological Biomarkers Market, by End-user
8.1. Introduction
8.2. Hospital Laboratories
8.3. Independent Clinical Diagnostic Centers
8.4. Research Organizations
9. Americas Neurological Biomarkers Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Neurological Biomarkers Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Neurological Biomarkers Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Acumen Pharmaceuticals, Inc
13.1.3. Alseres Pharmaceuticals, Inc.
13.1.4. Bio-Rad Laboratories, Inc.
13.1.5. bioMérieux SA
13.1.6. Imagilys
13.1.7. inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc.
13.1.8. IXICO PLC
13.1.9. Merck KGaA
13.1.10. Proteome Sciences PLC
13.1.11. QIAGEN GmbH
13.1.12. Quanterix Corporation
13.1.13. Quest Diagnostics Incorporated
13.1.14. Rules-Based Medicine by Q2 Solutions
13.1.15. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. NEUROLOGICAL BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 2. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022 VS 2030
FIGURE 3. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 5. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 6. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 7. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 8. NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
FIGURE 9. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 10. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 17. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 5. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 10. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 15. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 146. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 147. NEUROLOGICAL BIOMARKERS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Acumen Pharmaceuticals, Inc
  • Alseres Pharmaceuticals, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Imagilys
  • inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc.
  • IXICO PLC
  • Merck KGaA
  • Proteome Sciences PLC
  • QIAGEN GmbH
  • Quanterix Corporation
  • Quest Diagnostics Incorporated
  • Rules-Based Medicine by Q2 Solutions
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 10.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.56 Billion
Compound Annual Growth Rate14.0%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), Type, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), Type, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases - Global Strategic Business Report - Product Image

Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Neurological Biomarkers Global Market Report 2024 - Product Image

Neurological Biomarkers Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Neurological Biomarker Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Neurological Biomarker Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 146 Pages
  • Global
From

About the Neurological Biomarker Market

A neurological biomarker is a biological indicator of a neurological disorder or disease. It is used to diagnose, monitor, and predict the progression of neurological diseases. Neurological biomarkers can be found in a variety of biological samples, such as blood, cerebrospinal fluid, and tissue. They can also be used to measure the effectiveness of treatments. Neurological biomarkers are becoming increasingly important in the field of personalized medicine, as they can provide a more accurate diagnosis and prognosis of neurological diseases. They can also be used to identify potential drug targets and to monitor the progression of neurological diseases. The neurological biomarker market is growing rapidly, driven by the increasing prevalence of neurological diseases, the development of new technologies, and the increasing demand for personalized medicine. The market is expected to continue to grow in the coming years, as more companies enter the market and develop new technologies. Some of the major companies in the neurological biomarker market include Bio-Rad Laboratories, Inc., BioMérieux SA, Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.